$INCY · INCYTE CORP
Incyte reported Q3 2026 results with total revenue of $1.56B (+14% YoY) and total net sales of $1.32B (+14% YoY). GAAP net loss was $784.8M (-$3.86/share), entirely distorted by a one-time $1.23B IPR&D charge from the $1.25B Vega Therapeutics acquisition. Excluding that charge, R&D grew only 11% YoY. The company raised full-year 2026 net sales guidance for Opzelura, Hematology/Oncology, and total net sales, reflecting strong commercial momentum across the portfolio.
- Total revenue of $1.56B, up 14% YoY, driven by 14% net sales growth to $1.32B.
- Jakafi net sales of $827M (+4% YoY); Opzelura cream $255M (+36% YoY); Hematology/Oncology $235M (+38% YoY).
- GAAP net loss of $784.8M (-$3.86/share) driven by a one-time $1.23B IPR&D expense from the Vega Therapeutics acquisition.
- Non-GAAP net loss of $730.8M (-$3.60/share); excluding Vega charge, R&D expenses rose only 11% YoY.
- Full-year 2026 net sales guidance raised: Opzelura to $1,100-$1,120M, Heme/Onc to $890-$910M, total net sales to $5,210-$5,300M.
Extended-hours trading shows INCY at $117.06, up 0.16% from the regular close — a muted reaction suggesting the Vega-driven GAAP loss was well-telegraphed and the market is focused on the raised revenue guidance and pipeline catalysts.
The Vega charge masks accelerating commercial execution — core ex-Jakafi products grew 36-38% — while four pivotal Phase 3 readouts and a potential EU povorcitinib approval land by Q1 2027.
Incyte's core business ex-Jakafi is accelerating (Opzelura +36%, Heme/Onc +38%), mirroring a broader mid-cap biotech trend of diversifying beyond legacy blockbusters. The Vega acquisition adds a Phase 3 VWD asset, competing with Takeda and Sanofi in the rare hematology space.
The $1.23B Vega IPR&D charge drove a massive GAAP operating loss of $708.4M; the Vega deal also carries up to $750M in contingent sales milestones. Pipeline concentration risk is evident with multiple Phase 3 readouts (povorcitinib in PN, ruxolitinib cream in HS) expected by year-end 2026.